Hi Red. This may be a stupid question but the thought just occurred to me. Why would anyone buy shares of the "spin out" when the asset is already included in our share price and our share price reflects that? If the market is not valuing the diagnostics under the AMBS umbrella, why would we think that it would command anything other than what it has commanded, which is zero? (Pretty much) I just don't see any value in the diagnostics that would make anyone want it. No one has so far. Lympro changing the math would/should have happened long ago. We are all assuming that a spin out would be successful. Am I missing something?
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links